Publication
Title
ALK-inhibitors in NSCLC : a tabulated review of randomised phase III trials
Author
Abstract
Three inhibitors ALK-inhibitors have been assessed in six randomised phase III trials in patients with advanced anaplastic lymphoma kinase (ALK) positive Non Small-Cell Lung Cancer (NSCLC). Patient and tumour characteristics, efficacy, and safety results are summarised in Tables 1, 2, and 3, respectively. Progression-free survival was the primary endpoint in all trials. In first-line, alectinib was superior to crizotonib, and both crizotinib and ceritinib were superior to pemetrexed plus platinum. Crizotinib and ceritinib were superior to pemetrexed or docetaxel in previously treated patients.
Language
English
Source (journal)
Belgian journal of medical oncology. - Amsterdam, 2007, currens
Publication
Amsterdam : 2018
ISSN
1784-7141
Volume/pages
12:6(2018), p. 275-278
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identification
Creation 25.09.2018
Last edited 15.07.2021
To cite this reference